Detalhe da pesquisa
1.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Invest New Drugs
; 42(1): 145-159, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324085
2.
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Breast Cancer Res Treat
; 198(3): 487-498, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36853577
3.
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Future Oncol
; 13(4): 307-320, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27739325
4.
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
J Neurooncol
; 122(2): 409-17, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25682091
5.
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Invest New Drugs
; 32(5): 904-12, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24764124
6.
Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A.
J Biol Chem
; 286(45): 38960-8, 2011 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-21890637
7.
Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
Bioorg Med Chem Lett
; 22(24): 7615-22, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23103095
8.
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.
Bioorg Med Chem
; 20(15): 4635-45, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22766219
9.
PARP inhibitors attenuate chemotherapy-induced painful neuropathy.
J Peripher Nerv Syst
; 17(3): 324-30, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22971094
10.
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Cancer Chemother Pharmacol
; 89(5): 721-735, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35435472
11.
Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Bioorg Med Chem Lett
; 20(3): 1023-6, 2010 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20045315
12.
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.
Mol Cancer Ther
; 8(2): 386-93, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19208828
13.
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Neuro Oncol
; 22(6): 875-885, 2020 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32009149
14.
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Mol Cancer Res
; 6(10): 1621-9, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18922977
15.
Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Bioorg Med Chem Lett
; 19(15): 4050-4, 2009 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19553114
16.
Phase 0 trials: an industry perspective.
Clin Cancer Res
; 14(12): 3683-8, 2008 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18559583
17.
Optimal two-stage designs for exploratory basket trials.
Contemp Clin Trials
; 85: 105807, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31260789
18.
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Anal Biochem
; 381(2): 240-7, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18674509
19.
Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.
Bioorg Med Chem Lett
; 18(19): 5206-8, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18790640
20.
Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.
Bioorg Med Chem Lett
; 18(14): 3955-8, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18586490